Ospedale Santa Maria delle Croci

Ravenna 11 trials 5 recruiting

11 Registered trials

5 Currently recruiting

Organisation

Ospedale Santa Maria delle Croci

Location

Ravenna, Italy

Identifier

ORL-000008922

Address

V. Le Randi 5, 48121, Italy

Departments

Dipartimento di Oncologia ed Ematologia
Haematology
Hematology
Materno infantile
Nefrologia
Oncologia
Oncologia Medica
Oncology
U.O. Oncologia Medica
UOC di Cardiologia

Clinical trials at this site (11)

Search interface

A PROJECT FOR TWO MULTICENTRE, PROSPECTIVE OPEN LABEL RANDOMIZED CLINICAL STUDIES TO EVALUATE THE EFFECT OF TARGETED THERAPY BASED ON KIDNEY… Pending

2024-517861-18-00 Idiopathic IgA nephropathy (IgAN) 5
Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET deregulation Pending

2024-518386-95-02 Non small-cell lung cancer 4
Personalized antibiotic TREATment for febrile Urinary Tract Infections in children (TREAT-UTI study): multicenter randomized controlled tria… Pending

2025-520622-38-00 Urinary Tract Infections 5
A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tum… Pending

2025-521209-42-00 advanced colorectal cancer with wild-type RAS and right 6
Pharmacological optimization in prevention in Heart Failure: A Sex-gap? Recruiting

2025-520660-18-00 Heart Failure 6 2026-05-08
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor (BTKi) and a Bcell Lymphoma-2 Inhibit… Recruiting

2025-521088-10-00 Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia 4 2025-10-23
A Study of BMS-986504 in Combination with Pembrolizumab Plus Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line M… Recruiting

2025-521511-40-00 metastatic non-small cell lung cancer 10 2025-11-18
Phase II study of axitinib intensification plus standard of care (SOC) compared to SOC alone after induction with nivolumab plus ipilimumab … Recruiting

2024-511397-70-00 metastatic renal cell carcinoma (mRCC) 4 2024-05-06
MagnetisMM-6: A Phase 3 Study of Elranatamab (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Bortezomib + Lenalidomide + Dex… Recruiting

2024-514139-50-00 Multiple myeloma 5 2022-11-14
Optimizing MATRix, a combination of Methotrexate, Ara-C, Thiotepa and Rituximab given as an induction therapy, de-escalated in duration and … Ended

2024-514473-21-00 Primary diffuse large B-cell lymphoma (DLBCL) of the ce 5 2021-06-21
Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab (A-Brave) Ended

2024-514515-10-00 Breast Cancer 5 2016-06-16